ALK rearrangements in cancer
Cancer type | Frequency of ALK rearrangements | ALK fusion partner gene | Location of fusion partner | References |
---|---|---|---|---|
NSCLC | 3–7% | TPR | 1q31.1 | (2, 40–45) |
CRIM1 | 2p22.2 | |||
EML4a | 2p21 | |||
STRN | 2p22.2 | |||
TFG | 3q12.2 | |||
HIP1 | 7q11.23 | |||
PTPN3 | 9q31 | |||
KIF5B | 10p11.22 | |||
KLC1 | 14q32.3 | |||
CLTC | 17q23.1 | |||
ALCL | ∼55% (in adults) | TPM3 | 1q21.3 | (1, 21–29) |
ATIC | 2q35 | |||
TFG | 3q12.2 | |||
NPM1a | 5q35.1 | |||
TRAF1 | 9q33.2 | |||
CLTC | 17q23.1 | |||
RNF213 | 17q25.3 | |||
TPM4 | 19p13.1 | |||
MYH9 | 22q12.3 | |||
MSN | Xq12 | |||
IMT | Up to 50% | TPM3 | 1q21.3 | (30–37) |
RANBP2 | 2q13 | |||
ATIC | 2q35 | |||
SEC31A | 4q21.22 | |||
CARS | 11p15.4 | |||
PPFIBP1 | 12p11 | |||
CLTC | 17q23.1 | |||
TPM4 | 19p13.1 | |||
DLBCL | <1% | RANBP2 | 2q13 | (164–171) |
EML4 | 2p21 | |||
SEC31A | 4q21.22 | |||
SQSTM1 | 5q35 | |||
NPM1 | 5q35.1 | |||
CLTC | 17q23.1 | |||
Colorectal cancer | <1% | EML4 | 2p21 | (172–175) |
WDCP | 2p23.3 | |||
Breast cancer | N.D. | EML4 | 2p21 | (173) |
RCC | <1% | TPM3 | 1q21.2 | (176–179) |
EML4 | 2p21 | |||
STRN | 2p22.2 | |||
VCL | 10q22.2 | |||
RMC | N.D. | VCL | 10q22.2 | (180) |
Esophageal cancer | N.D. | TPM4 | 19p13.1 | (181, 182) |
Ovarian cancer | N.D. | FN1 | 2q35 | (183) |
Abbreviations: TPR, translocated promoter region, nuclear basket protein; CRIM1, cysteine rich transmembrane BMP regulator 1; EML4, echinoderm microtubule associated protein like 4; STRN, striatin; TFG, TRK-fused gene; HIP1, huntingtin interacting protein 1; PTPN3, protein tyrosine phosphatase, nonreceptor type 3; KIF5B, kinesin family member 5B; KLC1, kinesin light chain 1; CLTC, clathrin heavy chain; ALCL, anaplastic large cell lymphoma; TPM3, tropomyosin 3; NPM1, nucleophosmin; TRAF1, TNF receptor associated factor 1; RNF213, ring finger protein 213; TPM4, tropomyosin 4; MYH9, myosin, heavy chain 9, nonmuscle; MSN, moesin; IMT, inflammatory myofibroblastic tumor; RANBP2, RAN binding protein 2; SEC31A, SEC31 homolog A; CARS, cysteinyl-tRNA synthetase; PPFIBP1, PTPRF interacting protein, binding protein 1; DLBCL, diffuse large B-cell lymphoma; SQSTM1, sequestosome 1; WDCP, WD repeat and coiled coil containing; N.D., not determined; RCC, renal cell carcinoma; VCL, vinculin; RMC, renal medullary carcinoma; FN1, fibronectin 1.
↵aEML4 and NPM1 are the most common fusion partner genes in NSCLC and ALCL, respectively.